"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Swenson, Luke C ^a   Pollock, Graham ^a   Wynhoven, Brian ^a   Mo, Theresa ^a   Dong, Winnie ^a   Hogg, Robert S ^a,c   Montaner, Julio S G ^a,b   Harrigan, P Richard ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CANADA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FOLLOW UP; GENE LOCATION; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; POPULATION DISTRIBUTION; VIRUS LOAD; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FORECASTING; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONLINEAR SYSTEM; PHENOTYPE; PROFESSIONAL PRACTICE; PROGNOSIS; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; FORECASTING; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; NONLINEAR DYNAMICS; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL PRACTICE; PROGNOSIS; TREATMENT FAILURE; VIRAL LOAD;

EID: 79952094581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017402     Document Type: Article

References (22)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. (2000) A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14: F83-93.
2. Durant J, Clevenbergh P, Halfon P, Delguidice P, Porsin S, et al. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353: 2195-9.
3. Haubrich R, Demeter L, (2001) International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 26 (Suppl 1): S51-9.
4. Vandamme AM, Houyez F, Banhegyi D, Clotet B, De Schrijver G, et al. (2001) Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 6: 21-39.
5. Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, et al. (2001) Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15: 1471-5.
6. Sturmer M, Doerr HW, Staszewski S, Preiser W, (2003) Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 8: 239-44.
7. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, et al. (2002) Clinical Utility of HIV genotyping and expert advice: the Havana trial. AIDS 16: 209-218.
8. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, et al. (2000) Persisting long-term benefit of genotype-guided treatment for HIV-1 infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 5: 65-70.
9. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002) Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16: 727-736.
10. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, et al. (2000) World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15: 1671-1677.
11. Hoffman C, Rockstroh JK, Kamps BS, (2007) HIV Medicine. 15th Edition. Paris Flying Publisher.
12. Haubrich R, (2001) Improving the utility of phenotype resistance assays: New cut-points and interpretation. Advanced Sudies in Nursing 1: 486-490.
13. Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, et al. (2008) Determination of Clinically Relevant Cut-offs for HIV-1 Phenotypic Resistance Estimates through a Combined Analysis of Clinical Trial and Cohort Data. J Acquir Immune Defic Syndr 48: 26-34.
14. Dong W, Wynhoven B, Mo T, Hall T, Galli RA, et al. Performance of RE_Call basecalling software for high-throughput HIV Drug resistance basecalling using in-house methods. [Abstract TuPeB4598]. XIV International AIDS Conference; 2002; Barcelona, Spain.
15. Brooks JI, Woods CK, Merks H, Wynhoven B, Hall TA, et al. Evaluation of an automated sequence analysis tool to standardize HIV genotyping results. [Abstract O061]. Canadian Conference on HIV/AIDS Research; 2009; Vancouver, BC, Canada.
16. Brooks JI, Woods C, Merks H, Wynhoven B, Hall TA, et al. Evaluation of a Web-Based Automated Sequence Analysis Tool to Standardize HIV Genotyping Results. [Abstract]. 49th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 12-15, 2009.
17. Huang X, Zhang J, (1996) Methods for comparing a DNA sequence with a protein sequence, Computer Applications in the Biosciences 12: 497-506.
18. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2009) Update of the Drug Resistance Mutations in HIV-1: December 2009. Topics in HIV Medicine 17 (5): 138-145.
19. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, et al. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171: 1411-9.
20. British Columbia Centre for Excellence in HIV/AIDS. The HIV/AIDS Drug Treatment Program Status Report, 2003.
21. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, et al. (2010) Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection. Clinical Infectious Diseases 50: 1, 98-105.
22. Kellam P, Larder BA, (1994) Recombinant virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother 38: 23-30.